ArticleScientific reports2026
Dose and parameter specific effects of curcumin on neuropathic pain, cavity formation, and non-coding RNA expression in a spinal cord injury model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neuropathic pain (NP) represents one of the most frequent complications following spinal cord injury (SCI) and is associated with dysregulation of non-coding RNAs (ncRNAs). Curcumin possesses anti-inflammatory and neuroprotective properties. This study investigated the dose-dependent effects of curcumin-a compound with anti-inflammatory and neuroprotective properties-on pain-related behaviors and ncRNA expression after SCI. Male Wistar rats (n = 8 per group) were randomly assigned to 5 groups: Control (no surgery, no treatment), Sham (only laminectomy), SCI (clip-compression injury at the T11-T12 vertebral level), Cur100 and Cur200 (Curcumin at 100 and 200 mg/kg given orally 30 min after SCI for 10 consecutive days). Behavioral tests (acetone drop for cold allodynia, tail-flick for thermal hyperalgesia) were conducted over six weeks. Histological (H&E staining for cavity size) and molecular (qPCR for lncRNAs H19, GAS5, CRNDE and miRNAs miR-21-5p, miR-29a-3p) analyses were performed. Data were analyzed with PRISM software. At the endpoint, SCI induced significant cold allodynia, thermal hyperalgesia along with significant upregulation of all target ncRNAs. Curcumin treatment at both doses attenuated NP and modulated ncRNA expression in a parameter-dependent manner-where effects varied based on the specific outcome measured. The higher dose (200 mg/kg) provided greater neuroprotection and more effectively reduced thermal hyperalgesia, while the lower dose (100 mg/kg) was more potent in alleviating cold allodynia and selectively downregulating pro-inflammatory ncRNAs (H19, GAS5, miR-21-5p). These findings highlight the parameter-specificity of curcumin's therapeutic effects, suggesting that optimal dosing should be tailored according to the targeted pain modality and molecular pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.